Research Use Only — Not for Human or Veterinary Use.
Sign in
‹ Library

Semaglutide

GLP-1 / MetabolicResearch Use Only

Also known as: Ozempic (brand), Wegovy (brand), Rybelsus (brand)

Semaglutide is a long-acting GLP-1 receptor agonist frequently referenced in metabolic and weight-management research literature. Studies commonly describe its effects on appetite signaling, gastric emptying, and glucose-dependent insulin secretion. It is often discussed for its extended half-life relative to earlier GLP-1 analogs.

Typical range (research)
Research literature commonly references escalating weekly amounts in the ~0.25–2.4 mg/week range
Half-life
~7 days
Route
Subcutaneous (research)
Common use
Metabolic and weight-management research
Common vial sizes
5 mg · 10 mg · 20 mg
Storage
Store lyophilized powder refrigerated (2–8°C) and protected from light; once reconstituted, keep refrigerated and use within the timeframe supported by stability data.
Stacking notes
In research discussions it is sometimes referenced alongside cagrilintide (as a combined amylin/GLP-1 approach). Combining metabolic agents can compound gastrointestinal effects.

Reported side effects

NauseaReduced appetiteGastrointestinal upsetConstipation or diarrhea
Regulatory note: Prescription drug in Canada and the US; approved for type 2 diabetes and chronic weight management under brand names. Research-grade material is not for human use.
Calculate a dose →

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Not for human or veterinary use. Consult a licensed physician.